. Author manuscript; available in PMC: 2021 Sep 23.

Published in final edited form as: Cancer Chemother Pharmacol. 2020 Jan 1;85(4):827–830. doi: 10.1007/s00280-019-04021-y

Table 1.

Average pharmacokinetic parameters of panobinostat in nonhuman primate plasma after doses of 1.0, 1.8, 2.4, and 3.0 mg/kg

Dose (mg/kg)	Amt. given (mg)	Half-life (h⁻¹)	T_max (h)	C_max/dose (nM/mg)	Plasma AUC_inf/dose (h^*nM/mg)	Cl (L/h)
1.0 (n = 3)	12.0	32.2	0.900	0.918	10.5	322.3
1.8 (n = 3)	21.5	6.76	1.17	2.20	9.30	1544
2.4 (n = 3)	27.9	13.5	1.17	0.861	5.88	821.5
3.0 (n = 3)	35.5	13.4	1.00	1.12	4.97	800.3
Average	24.2	16.5	1.06	1.27	7.66	872.0
Std. dev	9.96	11.0	0.133	0.627	2.66	503.8
%CV	41.1	66.5	12.6	49.2	34.7	57.77

There were no quantifiable levels of panobinostat in the CSF